These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21482024)

  • 1. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
    Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
    Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
    Zhang X; Yashiro M; Ren J; Hirakawa K
    Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
    Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
    Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
    Yashiro M; Shinto O; Nakamura K; Tendo M; Matsuoka T; Matsuzaki T; Kaizaki R; Miwa A; Hirakawa K
    Int J Cancer; 2010 Feb; 126(4):1004-16. PubMed ID: 19621385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of multidrug-resistant gastric cancer cell lines.
    Zhang X; Yashiro M; Qiu H; Nishii T; Matsuzaki T; Hirakawa K
    Anticancer Res; 2010 Mar; 30(3):915-21. PubMed ID: 20393015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
    Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
    Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma.
    Zhang X; Yashiro M; Ohira M; Ren J; Hirakawa K
    Cancer Sci; 2006 Sep; 97(9):938-44. PubMed ID: 16805821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
    Yashiro M; Nishii T; Hasegawa T; Matsuzaki T; Morisaki T; Fukuoka T; Hirakawa K
    Br J Cancer; 2013 Nov; 109(10):2619-28. PubMed ID: 24129235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
    Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
    World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
    Moro H; Hattori N; Nakamura Y; Kimura K; Imai T; Maeda M; Yashiro M; Ushijima T
    Gastric Cancer; 2020 Jan; 23(1):105-115. PubMed ID: 31555951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14.
    Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
    Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP.
    Nitta A; Chung YS; Nakata B; Yashiro M; Onoda N; Maeda K; Sawada T; Sowa M
    Cancer Chemother Pharmacol; 1997; 40(1):94-7. PubMed ID: 9137537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
    Torii Y; Kato R; Minami Y; Hasegawa K; Fujii T; Udagawa Y
    Anticancer Res; 2014 Jan; 34(1):107-15. PubMed ID: 24403450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells.
    Takahashi K; Tanaka M; Yashiro M; Matsumoto M; Ohtsuka A; Nakayama KI; Izumi Y; Nagayama K; Miura K; Iwao H; Shiota M
    Cancer Lett; 2016 Aug; 378(1):8-15. PubMed ID: 27157913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
    Wang X; Zuo D; Chen Y; Li W; Liu R; He Y; Ren L; Zhou L; Deng T; Wang X; Ying G; Ba Y
    Br J Cancer; 2014 Nov; 111(10):1965-76. PubMed ID: 25321193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model.
    Yashiro M; Shinto O; Nakamura K; Tendo M; Matsuoka T; Matsuzaki T; Kaizaki R; Ohira M; Miwa A; Hirakawa K
    Br J Cancer; 2009 Oct; 101(7):1100-6. PubMed ID: 19738610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.